# US 2012/0083507 A1 · Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083507 A1
- Document ID: US20120083507A1
- Status: Published application
- Kind: A1
- Application number: 13/315,046
- Filed: 2011-12-08
- Published: 2012-04-05
- Earliest claimed: 2008-08-18
- Assignees: Medicis Pharmaceutical Corporation
- Inventors: Jefferson J. Gregory
- Web page: https://patentgrep.com/patent/US20120083507A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7061: {Polyacrylates}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

## Claims

### Claim 1

A method for treating genital or perianal warts in a subject, the method comprising:
applying an imiquimod pharmaceutical cream formulated with 3.75% by weight imiquimod to the warts, once per day, each day, for up to about 8 consecutive weeks or until clearance is observed, whichever occurs earlier, to treat the warts.

### Claim 2 (depends on 1)

The method of claim 1, wherein the imiquimod pharmaceutical cream further comprises a pharmaceutically acceptable vehicle.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pharmaceutically acceptable vehicle comprises a member selected from the group consisting of a fatty acid, an emollient, an emulsifier, a thickener, a preservative, a humectant, water, or a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the fatty acid is selected from the group consisting of isostearic acid, linoleic acid, oleic acid, super purified oleic acid, and a combination thereof

### Claim 5 (depends on 3)

The method of claim 3, wherein the fatty acid is isostearic acid.

### Claim 6 (depends on 3)

The method of claim 3, wherein the fatty acid is present in an amount of between about 5% to about 25% by weight.

### Claim 7 (depends on 3)

The method of claim 3, wherein the emollient is selected from the group consisting of cetyl alcohol, stearyl alcohol, petrolatum, and a combination thereof.

### Claim 8 (depends on 3)

The method of claim 3, wherein the emollient is present in an amount of between about 5% to about 10% by weight.

### Claim 9 (depends on 3)

The method of claim 3, wherein the emulsifier is selected from the group consisting of polysorbate 60, sorbitan monostearate, and a combination thereof

### Claim 10 (depends on 3)

The method of claim 3, wherein the emulsifier is present in an amount of between about 2% to about 6% by weight.

### Claim 11 (depends on 3)

The method of claim 3, wherein the preservative is selected from the group consisting of methylparaben, propylparaben, benzyl alcohol, and a combination thereof

### Claim 12 (depends on 3)

The method of claim 3, wherein the humectant is glycerin.

### Claim 13 (depends on 3)

The method of claim 3, wherein the water is present in an amount of between about 45% to about 85% by weight.

### Claim 14 (depends on 2)

The method of claim 2, wherein the pharmaceutically acceptable vehicle consists of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, water, benzyl alcohol, methylparaben, and propylparaben.

### Claim 15 (depends on 1)

The method of claim 1, wherein the imiquimod pharmaceutical cream is selected from the group of 3.75% imiquimod pharmaceutical creams listed in Example 29.
